Therapeutics

Developing Next Generation Therapeutics for Healthy Life

Pipeline
Oncology/Immuno-Oncology
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
mAb for Next-Gen Immuno-Oncology Therapeutics
view more

Porustobart HBM4003

CTLA-4

Melanoma

CRC*

HCC*

NEN*

Global

Global

Global

Global

view more

HBM1020

B7H7/HHLA2

Solid Tumors

Global

HBM1022

CCR8

Solid Tumors

Global

HBM9014

LIFR

Solid Tumors

Global

Immune Cell Engager for Oncology

HBM7022

CLDN18.2×CD3

Solid Tumors

Global Out-License

view more

HBM7008

B7H4×4-1BB

Solid Tumors

Global

HBM7020

BCMA×CD3

Hematologic Carcinoma

Ex-China

HBM9027

PD-L1×CD40

Solid Tumors

Global

HBM7004

B7H4×CD3

Solid Tumors

Global

XDC Platform

HBM9033

MSLN ADC

Solid Tumors

Global Out-License

ADC Program

Undisclosed

Solid Tumors

Global

RDC Program

Undisclosed

Solid Tumors

Global

Inflammatory & Immunology Diseases
Product(Partners)
Target
Indication
Region
Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
FcRn-Targeted Therapies for Autoimmune Diseases
view more

Batoclimab HBM9161

FcRn

Myasthenia Gravis

Great China Rights Out-Licensed

Type 2 Pathways for Inflammatory & Immunology Diseases

HBM9378

TSLP

Asthma

COPD*

Global

Global

BsAb Programs

TSLP×
Undisclosed

Inflammatory Diseases

Global

Pathogenic B Cell Depletion for Autoimmune Diseases

HBM7020

BCMA×CD3

Autoimmune Diseases

Ex-China

TCE Program

CD19×CD3

Autoimmune Diseases

Global

BsAb Program

Undisclosed

Autoimmune Diseases

Global

TsAb Program

Undisclosed

Autoimmune Diseases

Global

  • PD1 / Chemo

  • Breakthrough Therapy Designation

* CRC = Colorectal Cancer

* HCC = Hepatocellular Carcinoma

* NEN = Neuroendocrine Neoplasm

* COPD = Chronic Obstructive Pulmonary Disease

Publications